Osteoporose des Mannes

Literatur

• 1 Allolio B, Dambacher M, Dreher R, Felsenberg D, Franke J, Kruse H -P, Leidig-Bruckner G, Ringe J D, Semler J, Willvonseder R, Ziegler R. Die Osteoporose des Mannes.  Med Klinik. 2000;  95 327-338
• 2 Eastell R, Boyle I T, Compston J, Cooper C, Fogelman I, Francis R M, Hosking D J, Purdie D W, Ralston S, Reeve J, Reid D M, Russell R GG, Stevenson J C. Management of male osteoporosis: report of the UK consensus group.  Q J Med. 1998;  91 71-92
• 3 Kurland E S, Cosman F, McMahon D J, Rosen C J, Lindsay R, Bilezikian J P. Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers.  J Clin Endocrinol Metab. 2000;  85 3069-3076
• 4 Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J, Adami S, Weber K, Lorenc R, Pietschmann P, Vandormael K, Lombardi A. Alendronate for the treatment of osteoporosis in men.  N Engl J Med. 2000;  343 604-610
• 5 Orwoll E S, Scheele W H, Clancy A D, Diez-Perrez A, Myers S L, Mitlak B H. Teriparatide therapy reduces the incidence of moderate or severe fractures in men with osteoporosis. NOF Fifth International Symposium: Clinical Advances in Osteoporosis, March 6 - 9, 2002, Honolulu, Hawaii, p.3
• 6 Reid D M, Adami S, Devogelaer J P, Chines A A. Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy.  Calcif Tissue Int. 2001;  69 242-247
• 7 Ringe J D. Osteoporosis in men. Martin Dunitz, London In: Treatment of metabolic bone disease. Management strategy and drug therapy (Eds.: D.Hosking, JD Ringe) 2000
• 8 Ringe J D. Alendronsäure: Erstes Bisphosphonat zur Osteoporose-Therapie bei Männern.  Arzneimitteltherapie. 2001;  19 111-114
• 9 Ringe J D. Osteoporose Dialog. 100 Fragen - 100 Antworten. (2. Auflage),. Georg Thieme Verlag, Stuttgart, New York 2003
• 10 Ringe J D, Dorst A J, Faber H. Osteoporosis in men -clinical assessment of 400 patients and 205 controls by risk factor analysis, densitometry, and x-ray findings.  Osteologie. 1997;  6 81-86
• 11 Ringe J D, Dorst A, Kipshoven C, Rovati L C, Setnikar I. Avoidance of vertebral fractures in men with idiopathic osteoporosis by a three year therapy with calcium and low-dose intermittent monoflurophosphate.  Osteoporos Int. 2000;  8 47-52
• 12 Ringe J D, Faber H, Dorst A. Alendronate treatment of established primary osteoporosis in men: Results of a 2-year prospective study.  J Clin Endocrinol Metab. 2001;  86 5252-5255
• 13 Ringe J D, Rovati L C. Treatment of osteoporosis in men with fluoride alone or in combination with bisphosphonates.  Calcified Tissue Int. 2001;  69 252-255
• 14 Ringe J D, Orwoll E, Daifotis A, Lombardi A. Treatment of male osteoporosis: Recent advances with alendronate.  Osteoporos Int. 2002;  13 195-199
• 15 Ringe J D, Dauhrer K, Dorst A, Faber H. Three year treatment results with alendronate vs. alfacalcidol in established primary osteoporosis in men.  J Bone Miner Res. 2002;  17 S368 (Suppl 1)
• 16 Ringe J D, Dorst A, Faber H, Ibach K, Preuss J. Risedronate treatment of established primary and secondary osteoporosis in men: 1-year results of a 3-year prospective study.  J Bone Miner Res. 2002;  17 S368 (Suppl 1)
• 17 Trovas G P, Lyritis G P, Galanos A, Raptou P, Constantelou E. A randomized trial of nasal spray salmon calcitonin in men with idiopathic osteoporosis: effects on bone mineral density and bone markers.  J Bone Miner Res. 2002;  17 521-527